2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1392

Azathioprine May be an Effective Steroid Sparing Agent in Patients with Isolated Recurrent Pericarditis
Abstract Number: 1393

Diagnostic Categorization of Ocular Sarcoidosis Based on the International Criteria Proposed By the First International Workshop on Ocular Sarcoidosis. a Case Series of 11 Spanish Patients
Abstract Number: 1394

Clinical Characteristics of Sarcoid Arthropathy: A Population-Based Study
Abstract Number: 1395

Prevalence and Significance of MEFV GENE Mutations in Patients with Sarcoidosis
Abstract Number: 1396

Long Term Outcome of Neurosarcoidosis
Abstract Number: 1397

Successful Treatment of Cardiac Sarcoidosis with Biologic and Immunosuppressive Combination Therapy
Abstract Number: 1398

Musculoskeletal and Serologic Findings in an Adult Cystic Fibrosis Clinic Population-a Systematic Review and Collation with Disease Status
Abstract Number: 1399

Patterns of Arthropathy in Patients with Cystic Fibrosis
Abstract Number: 1400

Hyperferritinemia and Fever in Adults
Abstract Number: 1401

Is There Any Difference Between Autoimmune or Hemato-Oncology Etiology of Macrophage Activation Syndrome?
Abstract Number: 1402

Development of Systemic Juvenile Idiopathic Arthritis Manifestations Following Remission of Hemophagocytic Lymphohistiocytosis
Abstract Number: 1403

Immune Related Adverse Events Associated with Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review of Case Reports
Abstract Number: 1404

Death and Infection Rates Appear Reduced in a Modern Cohort of ICU Patients with Rheumatic Disease
Abstract Number: 1405

Tocilizumab Serum Levels and Antidrug Antibodies and Its Relationship with Disease Activity in Rheumatic Diseases
Abstract Number: 1406

The Treatment of Undifferentiated Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].